Clinical hold lifted for late stage cadisegliatin program for diabetesCATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to ...

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...

Tv Therapeutics (VTVT) announced that the United States Food and Drug Administration has lifted the clinical hold on the cadisegliatin ...

VTV tracks the performance of the CRSP US Large ... The health care sector, which generated mid-single-digit earnings growth in 2024, is expected to produce 18% year-over-year earnings increase ...

VTV.vn - Various activities were held nationwide throughout the National Year of Biodiversity Restoration 2024, with about 40 events and activities ...

VTV.vn - The Argentine website Resumen Latinoamericano has published an article highlighting Vietnam’s strong commitment to ...

Saipa defeated Paykan 3-1 (25-20, 25-17, 25-27, 25-19) to win 2024/25 Iranian Women's Volleyball Premier League on Thursday.

On July 26, 2024, vTv Therapeutics announced a clinical hold on the CATT1 Phase 3 trial based on the discovery of a chromatographic signal in a human absorption, distribution, metabolism ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes. CATT1 Phase 3 trial expected to resume following submission of protocol amendment shorten ...